Evidence map›Paper›PMID 33463722›Full record

ArticleBritish journal of pharmacology2021

The human G protein-coupled ATP receptor P2Y

Georg Gruenbacher, Hubert Gander, Gabriele Dobler, Andrea Rahm, Dominik Klaver, Martin Thurnher

Open access · hybridAbstract read
In one paragraph

Article in British journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Crosstalk between purinergic receptor P2YCellular and molecular life sciences : CMLS · 2024
    Article
  8. Article
  9. P2YPurinergic signalling · 2023
    Review
  10. Article
  11. The P2YCellular and molecular life sciences : CMLS · 2022
    Article
  12. Article
  13. Review
  14. The human G protein-coupled ATP receptor P2YBritish journal of pharmacology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Georg GruenbacherImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Hubert GanderImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Gabriele DoblerImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Andrea RahmImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Dominik KlaverImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.
Martin ThurnherImmunotherapy Unit, Department of Urology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0001-9940-7326
Innsbruck Medical University · AT

Funding

Austrian Science Fund P28923-B28Austrian Science Fund P33640-B
6 · The paper itself

Abstract

background and purposeThe ATP receptor P2Y EXPERIMENTAL APPROACH: Transcriptome and secretome profiling of ectopic P2Y KEY

resultsTemporal transcriptome profiling of P2Y CONCLUSIONS AND IMPLICATIONS: Targeting P2Y

Indexed as

Receptors, Purinergic P2Anti-Inflammatory AgentsHumansLipopolysaccharidesMacrophagesSignal TransductionTumor Necrosis Factor-alphaAnti-Inflammatory AgentsLipopolysaccharidesReceptors, Purinergic P2Tumor Necrosis Factor-alphaADAM17cyclic AMPinterleukin-1M2 macrophagesP2Y11soluble TNF receptorToll-like receptor

Identifiers

PMID33463722
PMCPMC9328440
OpenAlexW3125650262

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.